Market Report In Play PPDI

Johnson & Johnson Pharmaceutical Research & Development's completion of additional Phase III studies providing expanded safety and efficacy data for Priligy Co confirms that Johnson & Johnson Pharmaceutical Research & Development (JNJ) announced the completion of three additional Phase III studies using Priligy for the treatment of premature ejaculation. The new studies increase the number of subjects in the Priligy clinical dataset to more than 6,000 patients, providing an expanded safety database and confirmed efficacy

. Johnson & Johnson Pharmaceutical Research & Development announced its intention to review the new dataset with the U.S. Food and Drug Administration. "Our hope is that these data will provide additional safety and efficacy information in support of the Priligy new drug application," said Fred Eshelman, PPDI's chief executive officer. "We are pleased that our partner Janssen-Cilag continues to obtain clinical data for Priligy in pursuit of additional marketing approvals."


Read more!